EFFECTS OF A YERBA MATE EXTRACT IN REDUCING METABOLIC SYNDROME IN OVERWEIGHT INDIVIDUALS

Launched by UNIVERSIDADE FEDERAL DA FRONTEIRA SUL · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of yerba mate extract, a traditional drink known for its high antioxidant properties, on reducing metabolic syndrome in overweight individuals. Metabolic syndrome includes conditions like high blood pressure, high blood sugar, and unhealthy cholesterol levels, which can increase the risk of diabetes and heart disease. The trial will involve 80 participants aged between 40 and 65 who are overweight but do not have a history of heart disease or are taking certain medications. Participants will be asked to continue their usual diet and physical activity while consuming either the yerba mate extract or a placebo (a non-active substance) three times a day for 90 days.

Eligible participants should not have uncontrolled metabolic or endocrine diseases, recent significant weight changes, or specific dietary restrictions such as vegetarianism or veganism. Throughout the study, researchers will monitor various health indicators, including body measurements and blood samples, to see if the yerba mate extract positively impacts metabolic and inflammatory markers. This trial aims to provide valuable insights into how natural food sources like yerba mate can help improve health in overweight individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. men and women;
• • 2. aged between 40 and 65 years;
• • 3. with no previous cardiovascular history;
• • 4. individuals who are non-smokers or who have stopped smoking in the last 3 years;
• • 5. individuals who agree to maintain a habitual diet and physical activity;
• • 6. individuals who agree to maintain habitual consumption of polyphenol-rich beverages (yerba mate, teas, coffee, wine, cocoa, soy milk and fruit juice) during the course of the study;
• • 7. individuals who are not taking hypoglycemic, antihypertensive or anticholesterolemic drugs and;
• • 8. individuals who are overweight or obese (BMI≥25 to 34 Kg/m2 );
• • 9. individuals who have given up nutritional monitoring at least 3 months or who are undergoing nutritional treatment, but who are not showing weight changes of \>5% in the last 3 months.
• Exclusion Criteria:
• • 1. diagnosis uncontrolled metabolic or endocrine pathologies;
• • 2. who have undergone obesity surgery;
• • 3. post-menopausal women;
• • 4. pregnant and breastfeeding women;
• • 5. use of antipsychotics;
• • 6. with a vegetarian or vegan diet;
• • 7. who use probiotics and food supplements with antioxidant characteristics;
• • 8. those who have had a weight change of more than 10% in the last 3 months; 9) in treatment for excess body weight (hypocaloric diet or current nutritional treatment);
• • 10) smokers or chronic alcoholics; 11) Severe hypertension, history of cardiovascular disease with clinical complications such as: acute myocardial infarction and other coronary heart disease; 12) individuals with known malignant neoplasms, gastrointestinal diseases, kidney disease and/or liver disease.